Fig. 1From: A distinct molecular mutational profile and its clinical impact in essential thrombocythemia and primary myelofibrosis patientsDistribution of JAK2 V617F, MPL, and CALR mutations in patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF)Back to article page
